Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Microsc Microanal ; 30(3): 521-538, 2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38709559

ABSTRACT

Leishmaniasis is a neglected tropical disease (endemic in 99 countries) caused by parasitic protozoa of the genus Leishmania. As treatment options are limited, there is an unmet need for new drugs. The hydroxynaphthoquinone class of compounds demonstrates broad-spectrum activity against protozoan parasites. Buparvaquone (BPQ), a member of this class, is the only drug licensed for the treatment of theileriosis. BPQ has shown promising antileishmanial activity but its mode of action is largely unknown. The aim of this study was to evaluate the ultrastructural and physiological effects of BPQ for elucidating the mechanisms underlying the in vitro antiproliferative activity in Leishmania donovani. Transmission and scanning electron microscopy analyses of BPQ-treated parasites revealed ultrastructural effects characteristic of apoptosis-like cell death, which include alterations in the nucleus, mitochondrion, kinetoplast, flagella, and the flagellar pocket. Using flow cytometry, laser scanning confocal microscopy, and fluorometry, we found that BPQ induced caspase-independent apoptosis-like cell death by losing plasma membrane phospholipid asymmetry and cell cycle arrest at sub-G0/G1 phase. Depolarization of the mitochondrial membrane leads to the generation of oxidative stress and impaired ATP synthesis followed by disruption of intracellular calcium homeostasis. Collectively, these findings provide valuable mechanistic insights and demonstrate BPQ's potential for development as an antileishmanial agent.


Subject(s)
Antiprotozoal Agents , Apoptosis , Leishmania donovani , Mitochondria , Naphthoquinones , Leishmania donovani/drug effects , Leishmania donovani/physiology , Mitochondria/drug effects , Mitochondria/ultrastructure , Apoptosis/drug effects , Antiprotozoal Agents/pharmacology , Naphthoquinones/pharmacology , Caspases/metabolism , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission
2.
Eur J Med Chem ; 257: 115524, 2023 Sep 05.
Article in English | MEDLINE | ID: mdl-37290183

ABSTRACT

Towards identification of novel therapeutic candidates, a series of quinazolinone-based acetamide derivatives were synthesized and assessed for their anti-leishmanial efficacy. Amongst synthesized derivatives, compounds F12, F27 and F30 demonstrated remarkable activity towards intracellular L. donovani amastigotes in vitro, with IC50 values of 5.76 ± 0.84 µM, 3.39 ± 0.85 µM and 8.26 ± 1.23 µM against promastigotes, and 6.02 µM ± 0.52, 3.55 ± 0.22 µM and 6.23 ± 0.13 µM against amastigotes, respectively. Oral administration of compounds F12 and F27 entailed >85% reduction in organ parasite burden in L. donovani-infected BALB/c mice and hamsters, by promoting host-protective Th1 cytokine response. In host J774 macrophages, mechanistic studies revealed inhibition of PI3K/Akt/CREB axis, resulting in a decrease of IL-10 versus IL-12 release upon F27 treatment. In silico docking studies conducted with lead compound, F27 demonstrated plausible inhibition of Leishmania prolyl-tRNA synthetase, which was validated via detection of decreased proline levels in parasites and induction of amino acid starvation, leading to G1 cell cycle arrest and autophagy-mediated programmed cell death of L. donovani promastigotes. Structure-activity analysis and study of pharmacokinetic and physicochemical parameters suggest oral availability and underscore F27 as a promising lead for anti-leishmanial drug development.


Subject(s)
Antiprotozoal Agents , Leishmania donovani , Leishmaniasis, Visceral , Cricetinae , Animals , Mice , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/metabolism , Quinazolinones/pharmacology , Quinazolinones/therapeutic use , Quinazolinones/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Acetamides/pharmacology , Acetamides/therapeutic use , Acetamides/metabolism , Mice, Inbred BALB C
3.
Biochem Biophys Res Commun ; 471(1): 205-12, 2016 Feb 26.
Article in English | MEDLINE | ID: mdl-26826385

ABSTRACT

Hypoxia promotes cancer progression, and metastasis. The major protein expressed in hypoxic solid cancer is hypoxia-inducible factor 1 (HIF1). We show that enhanced phosphorylation of a conventional protein kinase C isoform, PKCα, at threonine 638 (T(638)) by hypoxia-mimetic cobalt chloride induces HIF1α in nuclei of gastric epithelial cells (GECs). Moreover, phospho-T(638)-PKCα (P-PKCα) interacts with p300-HIF1α complex in the nuclei of hypoxic GECs and PKCα phosphorylation at T(638) enhances transcriptional activity of HIF1α. High P-PKCα expression in neoplastic gastric cancer biopsy samples as compared to nonneoplastic samples suggests that P-PKCα might act as an indicator of gastric cancer progression.


Subject(s)
Cell Nucleus/metabolism , Cobalt/administration & dosage , Gastric Mucosa/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Protein Kinase C-alpha/metabolism , Cell Hypoxia/drug effects , Cell Hypoxia/physiology , Cell Line , Cell Nucleus/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Gastric Mucosa/drug effects , Humans , Phosphorylation/drug effects , Phosphorylation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...